MAY 09, 2024 | 5:53 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT KATE RAISES THE BAR FOR DMD GENE THERAPY BY At ASGCT meeting, Westlake and Versant-backed Kate Therapeutics shows its AAV gene therapy targets muscle, heart in primateshttps://www.biocentury.com/article/652365/kate-raises-the-bar-for-dmd-gene-therapy© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 09, 2024 | 3:24 PM PDT | BIOCENTURY | FINANCE VENTURE REPORT: BIG ROUNDS FOR BLUEJAY, ATTOVIA AND ZENAS BY Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverThttps://www.biocentury.com/article/652374/venture-report-big-rounds-for-bluejay-attovia-and-zenas© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 09, 2024 | 2:41 PM PDT | BIOCENTURY | POLITICS, POLICY & LAW HOUSE OVERSIGHT CHAIR COMER LOOKS TO ENLIST FDA IN CHINA RIVALRY BY Former FDA official concerned about unintended consequences of bringing agency into geopolitical competitionhttps://www.biocentury.com/article/652389/house-oversight-chair-comer-looks-to-enlist-fda-in-china-rivalry© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 09, 2024 | 2:15 PM PDT | BIOCENTURY | MANAGEMENT TRACKS C-SUITE CHANGES AT ACELYRIN COULD SIGNAL REPRIORITIZATIONS IN PIPELINE BY With CEO Shao-Lee Lin leaving, the company said it’s aiming to preserve cash resources, with a series of decision-driving clinical catalysts on the wayhttps://www.biocentury.com/article/652388/c-suite-changes-at-acelyrin-could-signal-reprioritizations-in-pipeline© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 08, 2024 | 5:59 PM PDT | BIOCENTURY | MANAGEMENT TRACKS MEYRICK SUCCEEDING CMO HARRIS AT RADIOPHARMA ITM BY Plus: ALX hires Dillon and updates from Obsidian, YS and morehttps://www.biocentury.com/article/652367/meyrick-succeeding-cmo-harris-at-radiopharma-itm© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 08, 2024 | 5:49 PM PDT | BIOCENTURY | FINANCE BIO€QUITY EUROPE 2024 PREVIEW: RISING ABOVE THE NOISE  BY Looking ahead to the twenty-fourth incarnation of BioCentury’s European meetinghttps://www.biocentury.com/article/652371/bio-quity-europe-2024-preview-rising-above-the-noise© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 08, 2024 | 5:43 PM PDT | BIOCENTURY | POLITICS, POLICY & LAW BIO SURVEY SHOWS IMPACTS OF BIOSECURE ACT BY Abrupt decoupling from Chinese CDMOs and CMOs would devastate patients, biopharmashttps://www.biocentury.com/article/652385/bio-survey-shows-impacts-of-biosecure-act© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 08, 2024 | 3:45 PM PDT | BIOCENTURY | POLITICS, POLICY & LAW BIOSECURE ACT REVISIONS TO TARGET MEDICARE, MEDICAID, VA REIMBURSEMENT BY Release of new version expected soon from Select Committee on the Chinese Communist Party https://www.biocentury.com/article/652377/biosecure-act-revisions-to-target-medicare-medicaid-va-reimbursement© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 08, 2024 | 11:01 AM PDT | BIOCENTURY | EMERGING COMPANY PROFILE AVICENNA: USING MACHINE LEARNING TO SKIP THE HIT-TO-LEAD PHASE BY Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compoundshttps://www.biocentury.com/article/652350/avicenna-using-machine-learning-to-skip-the-hit-to-lead-phase© 2024 BioCentury Inc. All Rights Reserved ..read more

MAY 07, 2024 | 4:43 PM PDT | BIOCENTURY | PRODUCT DEVELOPMENT SECOND PATIENT DEATH IN PFIZER’S DMD GENE THERAPY STUDIES RENEWS SAFETY CONCERNS BY It’s not yet clear if the new patient death Pfizer reported in Phase II DAYLIGHT study of fordadistrogene movaparvovec is treatment-relatedhttps://www.biocentury.com/article/652357/second-patient-death-in-pfizer-s-dmd-gene-therapy-studies-renews-safety-concerns© 2024 BioCentury Inc. All Rights Reserved ..read more